Key result
Tissue-type plasminogen activator after CABG was associated with lower mean stenosis severity of saphenous vein grafts at 3 months compared with conventional treatment (p<0.05).
Why the study?
Does tissue-type plasminogen activator (t-PA) added to dual antiplatelet therapy reduce graft restenosis in patients after coronary artery bypass grafting?
Observational (n=37)
Does tissue-type plasminogen activator (t-PA) added to dual antiplatelet therapy reduce graft restenosis in patients after coronary artery bypass grafting?
Answers are grounded in this paper and cite their sources.
Early postoperative intravenous t-PA may reduce the severity of saphenous vein graft stenosis at 3 months following CABG, though it did not significantly alter overall graft patency rates in this small observational study.
OBJECTIVE: To explore the feasibility and safety of using tissue-type plasminogen activator (t-PA) to prevent graft restenosis after coronary artery bypass grafting (CABG). METHODS: In this prospective observational study, 37 patients underwent CABG between June 2009 and May 2013. These patients were grouped according to the anti-coagulation strategy after surgery: t-PA (n = 12) and conventional treatments (n = 25). In the t-PA group, the patients received acetylsalicylic acid (ASA) and clopidogrel plus intravenous infusion of t-PA (0.25 mg/kg/day) starting at 24 h after surgery and that lasted for 3 days. In the conventional group, the patients received only ASA and clopidogrel. 64-row spiral computed tomographic coronary angiography was performed at 1 week, 1, and 3 months after surgery to evaluate the patency of the graft vessel. RESULTS: The mean stenosis severity of the saphenous vein grafts was lower in the t-PA group compared with the conventional group at 3 months after surgery (p < 0.05), but there was no significant difference at 1 week and 1 month (p > 0.05). The patency rate of the grafts was not significantly different between the two groups at 1 week, 1, and 3 months after surgery (p > 0.05). CONCLUSION: Early application of t-PA after CABG was feasible and safe, and might help prevent early restenosis of SV grafts. Additional clinical randomized trials are necessary to address this issue.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) conducted an observational in Coronary artery bypass grafting (n=37). Tissue-type plasminogen activator (t-PA) vs. Conventional treatments (ASA and clopidogrel) was evaluated on Mean stenosis severity of the saphenous vein grafts at 3 months (p=<0.05). Tissue-type plasminogen activator after CABG was associated with lower mean stenosis severity of saphenous vein grafts at 3 months compared with conventional treatment (p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: